@article{10c06ed633fd4162b7f2534e230e09bc,
title = "Treatments for AD: towards the right target at the right time",
author = "{van der Flier}, {Wiesje M.} and Tijms, {Betty M.}",
note = "Funding Information: Research programmes of W.M.v.d.F. have been funded by ZonMW, NWO, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.v.d.F. has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, NovoNordisk, European Brain Council. W.M.d.v.F. is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. W.M.v.d.F. participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. W.M.v.d.F. is a member of the steering committee of PAVE, and Think Brain Health. W.M.v.d.F. was associate editor of Alzheimer{\textquoteright}s Research & Therapy in 2020–2021. W.M.v.d.F. is an associate editor at Brain. B.M.T. declares no competing interests.",
year = "2023",
month = oct,
doi = "https://doi.org/10.1038/s41582-023-00869-0",
language = "English",
volume = "19",
pages = "581--582",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "10",
}